依达拉奉联合奥拉西坦在急性期原发性脑出血中的治疗作用

Effects of edaravone combined with oxiracetam in the treatment of patients with primary hematencephalon at acute stage

目的探讨依达拉奉联合奥拉西坦针对急性期原发性脑出血患者实施治疗的临床效果。方法选择我院2014年10月~2015年10月期间收治的136例急性期脑出血患者作为研究对象并实施随机分组治疗,对照组68例在实施常规治疗的同时予以奥拉西坦,研究组68例在实施对照组相同治疗方法的同时联合予以依达拉奉。将两组患者的临床效果进行对比。结果在神经功能缺损评分以及血肿体积具体数据方面,两组患者在接受治疗后均得以明显降低,研究组明显低于对照组（P〈0.05）;在临床治疗有效率方面,研究组明显高于对照组（P〈0.05）;两组研究对象均无严重不良反应发生（P〉0.05）。结论应用依达拉奉联合奥拉西坦针对急性期原发性脑出血患者实施治疗,能够产生明显的效果,有助于改善患者的神经功能缺损以及脑血肿等临床症状,对于促进患者康复具有积极意义。

Objective To explore the clinical effect of edaravone combined with oxiracetam in the treatment of primary hematencephalon at acute stage. Methods 136 patients with primary hematencephalon at acute stage who were in our hospital from October 2014 to October 2015 were randomly divided into research group and control group, 68 cases in each group. The control group was treated with oxiracetam and routine therapy, the research group was treated with edaravone based on the control group＇s therapy. The clinical effects of the two groups were compared. Results The neural function defect scores and hematoma volumes of the two groups after treatment were all lower or smaller than those before, and the research group＇s indexes were obviously better than those of the control group（P〈0.05）. The clinical effective rate of the research group was obviously higher than that of the control group（P〈0.05）. There were no serious adverse reactions in both two groups（P〈0.05）. Conclusion The therapy of edaravone combined with oxiracetam is effective in the treatment of patients with primary hematencephalon at acute stage, which alleviates patients＇ clinical symptoms of neural functional impairment and cephalophyma, and benefits the patients＇ recovery.